Literature DB >> 20735341

Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis.

Marina Papadia1, Carl Peter Herbort.   

Abstract

PURPOSE: To report a patient treated with infliximab for ankylosing spondylitis and HLA-B27 uveitis presenting with a scotoma in his left good eye due to infliximab-induced occipital demyelination mistaken for a uveitis recurrence.
DESIGN: Case report.
METHODS: Review of clinical features, visual field, and investigational procedures.
RESULTS: Loss of visual function could not be explained by mere ophthalmic examination. Magnetic resonance imaging showed several demyelinating lesions, explaining the patient's symptoms and signs. Infiliximab was discontinued and the scotoma disappeared.
CONCLUSION: This is the first report of infliximab-induced demyelination producing ocular symptoms and signs in a patient treated for uveitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735341     DOI: 10.3109/09273948.2010.496914

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  4 in total

Review 1.  The Use of Biologic Therapies in Uveitis.

Authors:  Sergio Schwartzman; Monica Schwartzman
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

2.  Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis.

Authors:  Junko Matsuda; Toshikatsu Kaburaki; Shigeto Kobayashi; Jiro Numaga
Journal:  Jpn J Ophthalmol       Date:  2012-10-30       Impact factor: 2.447

3.  Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.

Authors:  Denize Atan; Jarka Heissigerova; Lucia Kuffová; Aideen Hogan; Dara J Kilmartin; John V Forrester; Jeff L Bidwell; Andrew D Dick; Amanda J Churchill
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

Review 4.  Ocular side effects of antirheumatic medications: a qualitative review.

Authors:  Clara M Castillejo Becerra; Yue Ding; Beatrice Kenol; Andrew Hendershot; Alexa Simon Meara
Journal:  BMJ Open Ophthalmol       Date:  2020-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.